Intellia Therapeutics (NTLA) Total Current Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Current Liabilities data on file, last reported at $76.4 million in Q1 2026.

• Quarterly Total Current Liabilities fell 32.11% year-over-year to $76.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.4 million (down 32.11% YoY) and the FY2025 annual result came in at $103.9 million, down 6.29% from the prior year.
• Total Current Liabilities eased to $76.4 million in Q1 2026 per NTLA's latest filing, from $103.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $131.1 million in Q3 2022 and bottomed at $76.4 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $105.1 million (2024), against an average of $107.0 million.
• The widest annual swing landed in 2022, when Total Current Liabilities surged 107.75%; it then tumbled 32.11% in 2026.
• Tracing NTLA's Total Current Liabilities over 5 years: stood at $126.6 million in 2022, then decreased by 8.97% to $115.2 million in 2023, then retreated by 3.78% to $110.9 million in 2024, then decreased by 6.29% to $103.9 million in 2025, then fell by 26.41% to $76.4 million in 2026.
• Per Business Quant, the three latest NTLA Total Current Liabilities figures stand at $76.4 million (Q1 2026), $103.9 million (Q4 2025), and $93.7 million (Q3 2025).

Peer Comparison